


The Importance of the Pharmaceutical Industry for Sweden

March 2026

EXPORT



In 2025¹, Sweden exported pharmaceuticals worth SEK 154 billion, corresponding to 7.5% of Sweden's total exports.

Source: SCB




Pharmaceuticals are Sweden's second-largest product category², after motor vehicles.

Source: SCB

„The pharmaceutical industry is an important part of Sweden's total defence and contributes to the green transition“

THE PHARMACEUTICAL INDUSTRY'S TOTAL³ IMPACT



More than 85,000 jobs⁴

Source: Statistics Sweden (SCB), PwC analysis



SEK 190 billion contribution to GDP (3.5% of total GDP)

Source: Statistics Sweden (SCB), PwC analysis



SEK 40 billion in tax revenues each year

Source: Statistics Sweden (SCB), Lif analysis



SEK 13.6 billion in direct investments in Research & Development each year

Source: Statistics Sweden (SCB)

THE INDUSTRY'S PRESENCE IN SWEDEN



- 61 manufacturing facilities for approved medicines (i.e., products such as tablets and injections)
- 12 manufacturing facilities for the production of active substances (chemical or biological substances that constitute the active component in medicines)

Source: Läkemedelsverket 2023


¹Pharmaceutical base products and medicinal products | ²Medicinal and other pharmaceutical products (21.2 SPIN2015)

³Direct, indirect and induced effects | ⁴Full-time equivalents (FTEs)

Challenges Facing the Pharmaceutical Industry

PHARMACEUTICAL SALES


Largest pharmaceutical markets in 2024



The United States accounts for more than half of the global pharmaceutical market.

Source: IQVIA (MIDAS)

FEWER AND FEWER NEW MEDICINES ARE REACHING SWEDISH PATIENTS




Less than half of EU-approved medicines reach Swedish patients

The share of EU-approved reimbursed medicines is declining

Source: EFPIA WAIT Report

CLINICAL TRIALS

Number of Phase I–III study starts based on company headquarters, 2009–2024




Europe Is Losing Ground to the United States and China

Source: IQVIA, Global Trends in R&D 2025

SWEDEN IS A LOW-PRICE COUNTRY

Pharmaceutical prices in Sweden are nearly 18% below the average⁵



FEWER NEW MEDICINES ARE REACHING SWEDISH PATIENTS

Country	PhRMA Net expenditure on 500 new innovative medicines (% of GDP)	EFPIA Public net expenditure on new medicines over 10 years (% of GDP)
Belgium	0.23%	0.47%
Denmark	0.26%	0.30%
Estonia (retail only)	0.26%	0.32%
Finland	0.31%	0.29%
France	0.29%	0.45%
Germany	0.36%	0.59%
Greece	0.11%	0.28%
Ireland*	0.13%	0.36%
Italy	0.46%	0.46%
Latvia	0.27%	0.24%
Lithuania	0.29%	0.35%
Norway	0.27%	0.20%
Poland	0.29%	0.28%
Portugal	0.41%	0.46%
Slovakia	0.32%	0.44%
Slovenia	0.34%	0.77%
Spain	0.53%	0.67%
Sweden	0.21%	0.28%
Switzerland	0.24%	0.36%
United Kingdom	0.28%	0.30%
Hungary*	0.25%	0.17%
United States**	0.78%	1.16%
Austria	0.37%	0.47%

0.28% of GDP
Sweden ranks 17th out of 22

*Hungary's data on pharmaceutical expenditure refers only to the retail sector for the EFPIA method

*EFPIA uses GNI in current prices for Ireland, while PhRMA uses GDP

**U.S. figures refer to the total market (public, private, independent organisations), compared with EU countries where the expenditures are public only

Source: EFPIA

⁵Bilateral price comparisons for medicines without generic competition used in Sweden, 2025, percentage deviation. Source: TLV 2025